Vera Therapeutics reports positive final ORIGIN 3 data for atacicept in IgA nephropathy
FROM THE WIRE · MARKETS.BUSINESSINSIDER.COM
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGF...
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive late-stage data for a biotech; relevance is company-specific rather than market-wide.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The ORIGIN 3 final efficacy analysis of TRUTAKNA (atacicept-vymj) was positive.
- 02TRUTAKNA achieved statistical significance in all prespecified endpoints, including eGFR.
- 03The results were presented at ASN Kidney Week 2026 and published in the New England Journal of Medicine.